vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Orange County Bancorp, Inc. (OBT). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $33.0M, roughly 1.2× Orange County Bancorp, Inc.). Orange County Bancorp, Inc. runs the higher net margin — 37.6% vs -161.8%, a 199.4% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 20.6%). Orange County Bancorp, Inc. produced more free cash flow last quarter ($41.3M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.
IBRX vs OBT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $33.0M |
| Net Profit | $-61.9M | $12.4M |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | 41.4% |
| Net Margin | -161.8% | 37.6% |
| Revenue YoY | 407.0% | 20.6% |
| Net Profit YoY | -4.7% | 73.5% |
| EPS (diluted) | $-0.06 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $33.0M | ||
| Q3 25 | $32.1M | $33.7M | ||
| Q2 25 | $26.4M | $32.5M | ||
| Q1 25 | $16.5M | $28.0M | ||
| Q4 24 | $7.6M | $27.4M | ||
| Q3 24 | $6.1M | $27.1M | ||
| Q2 24 | — | $27.9M | ||
| Q1 24 | — | $25.3M |
| Q4 25 | $-61.9M | $12.4M | ||
| Q3 25 | $-67.3M | $10.0M | ||
| Q2 25 | $-92.6M | $10.5M | ||
| Q1 25 | $-129.6M | $8.7M | ||
| Q4 24 | $-59.2M | $7.2M | ||
| Q3 24 | $-85.7M | $3.2M | ||
| Q2 24 | — | $8.2M | ||
| Q1 24 | — | $9.3M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | 41.4% | ||
| Q3 25 | -173.5% | 38.6% | ||
| Q2 25 | -269.8% | 41.9% | ||
| Q1 25 | -390.1% | 40.3% | ||
| Q4 24 | -919.0% | 32.8% | ||
| Q3 24 | -1314.3% | 14.8% | ||
| Q2 24 | — | 36.6% | ||
| Q1 24 | — | 45.9% |
| Q4 25 | -161.8% | 37.6% | ||
| Q3 25 | -209.8% | 29.7% | ||
| Q2 25 | -350.3% | 32.2% | ||
| Q1 25 | -784.9% | 31.1% | ||
| Q4 24 | -783.4% | 26.2% | ||
| Q3 24 | -1404.0% | 11.8% | ||
| Q2 24 | — | 29.4% | ||
| Q1 24 | — | 36.7% |
| Q4 25 | $-0.06 | $0.94 | ||
| Q3 25 | $-0.07 | $0.75 | ||
| Q2 25 | $-0.10 | $0.87 | ||
| Q1 25 | $-0.15 | $0.77 | ||
| Q4 24 | $-0.08 | $0.64 | ||
| Q3 24 | $-0.14 | $0.28 | ||
| Q2 24 | — | $0.73 | ||
| Q1 24 | — | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $284.4M |
| Total Assets | $501.9M | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | — | ||
| Q3 25 | $257.8M | — | ||
| Q2 25 | $153.7M | — | ||
| Q1 25 | $61.6M | — | ||
| Q4 24 | $149.8M | — | ||
| Q3 24 | $130.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-500.5M | $284.4M | ||
| Q3 25 | $-524.3M | $270.1M | ||
| Q2 25 | $-570.7M | $252.6M | ||
| Q1 25 | $-591.4M | $201.3M | ||
| Q4 24 | $-489.1M | $185.5M | ||
| Q3 24 | $-745.1M | $193.1M | ||
| Q2 24 | — | $177.5M | ||
| Q1 24 | — | $168.7M |
| Q4 25 | $501.9M | $2.7B | ||
| Q3 25 | $519.0M | $2.6B | ||
| Q2 25 | $402.1M | $2.6B | ||
| Q1 25 | $303.8M | $2.6B | ||
| Q4 24 | $382.9M | $2.5B | ||
| Q3 24 | $364.6M | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $43.8M |
| Free Cash FlowOCF − Capex | $-71.3M | $41.3M |
| FCF MarginFCF / Revenue | -186.2% | 125.1% |
| Capex IntensityCapex / Revenue | 2.4% | 7.6% |
| Cash ConversionOCF / Net Profit | — | 3.53× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $69.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $43.8M | ||
| Q3 25 | $-68.9M | $30.2M | ||
| Q2 25 | $-79.7M | $-5.0M | ||
| Q1 25 | $-85.9M | $4.8M | ||
| Q4 24 | $-85.1M | $34.6M | ||
| Q3 24 | $-98.8M | $10.2M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $2.3M |
| Q4 25 | $-71.3M | $41.3M | ||
| Q3 25 | $-69.6M | $29.6M | ||
| Q2 25 | $-80.8M | $-5.7M | ||
| Q1 25 | $-87.0M | $4.3M | ||
| Q4 24 | $-87.3M | $32.9M | ||
| Q3 24 | $-101.6M | $10.0M | ||
| Q2 24 | — | $9.2M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | -186.2% | 125.1% | ||
| Q3 25 | -217.2% | 87.8% | ||
| Q2 25 | -305.9% | -17.5% | ||
| Q1 25 | -526.9% | 15.5% | ||
| Q4 24 | -1155.4% | 120.0% | ||
| Q3 24 | -1663.2% | 36.7% | ||
| Q2 24 | — | 32.8% | ||
| Q1 24 | — | 7.9% |
| Q4 25 | 2.4% | 7.6% | ||
| Q3 25 | 2.3% | 1.8% | ||
| Q2 25 | 4.1% | 2.3% | ||
| Q1 25 | 6.8% | 1.8% | ||
| Q4 24 | 28.0% | 6.3% | ||
| Q3 24 | 45.7% | 1.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.01× | ||
| Q2 25 | — | -0.47× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 4.83× | ||
| Q3 24 | — | 3.19× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
